Pituitary hyperplasia after goserelin (LHRH–analogue) therapy
| Autor: | Herbert Radner, Karl Pummer, S. Lax, G. Wandschneider, H. Höfler |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Male
endocrine system medicine.medical_specialty Pituitary gland Histology medicine.drug_class Buserelin Pathology and Forensic Medicine Adrenocorticotropic Hormone Anterior pituitary Pituitary Gland Anterior Physiology (medical) Internal medicine medicine Humans Neoplasm Metastasis Testosterone Aged Hyperplasia business.industry Goserelin Prostatic Neoplasms medicine.disease Androgen Immunohistochemistry Endocrinology medicine.anatomical_structure Neurology Growth Hormone Neurology (clinical) business Luteinizing hormone Orchiectomy medicine.drug Hormone |
| Zdroj: | Neuropathology and Applied Neurobiology. 17:75-81 |
| ISSN: | 1365-2990 0305-1846 |
| DOI: | 10.1111/j.1365-2990.1991.tb00696.x |
| Popis: | A 78–year–old male was treated with goserelin (Zoladex®) for 16 months for metastasizing prostate carcinoma. This therapy is clinically equivalent to orchidectomy, as the application of the luteinizing hormone–releasing hormone (LHRH)–analogue Zoladex® causes suppression of follicle–stimulating hormone (FSH) and luteinizing hormone (LH) by down–regulation of pituitary receptors. Consequently, testicular androgen production is inhibited and testosterone levels are decreased to castration levels. In the present case we found diffuse, partially nodular hyperplasia of growth hormone (GH) and adrenocorticotropin (ACTH) producing cells in the anterior pituitary gland at autopsy. As Zoladex® reduces pituitary receptors for releasing hormones (RH), a globally increased hypothalamic secretion of RH might be responsible for the ACTH– and the GH–cell hyperplasia. We cannot exclude that Zoladex® may cause not only adenomas in rat pituitary glands as Reported previously, but also a (nodular) hyperplasia of the pituitary gland in man. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text